@article{TCR13386,
author = {Sang-Yun Song and Cheol-Kyu Park and In-Jae Oh and Young-Chul Kim},
title = {Angiogenesis inhibitors for small cell lung cancer},
journal = {Translational Cancer Research},
volume = {6},
number = {Suppl 3},
year = {2017},
keywords = {},
abstract = {Small-cell lung cancer (SCLC) accounts for approximately 12–15% of all lung cancers and is characterized by a rapid growth rate and metastasis at the time of diagnosis. Despite its initial sensitivity to first-line chemotherapy, rapid acquisition of resistance to subsequent lines of therapy is usually observed. Although there is a plethora of new drugs being developed for non-small cell lung cancer (NSCLC), there is still a shortage of treatment regimens other than the combination therapy containing platinum and etoposide or irinotecan.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/13386}
}